BioSpace News Archive

Drug Development

Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta Phase I Trial in Advanced Ovarian Cancer

Dosing expected to begin in 1Q18.

January 8, 2018
·
4 min read
Drug Development

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase II Clinical Trials for Common Warts

Both trials evaluated the safety and efficacy of A-101 45% as compared to placebo (vehicle).

January 8, 2018
·
7 min read
Business

Inovalon Expects Fourth Quarter Revenue Growth of 18% to 20% and Adjusted EBITDA Growth of 78% Assuming the Midpoint, Consistent with Prior Guidance

Fourth quarter revenue expected to be between $113.5 million to $115.0 million, up 18% to 20% year-over-year as reported and 13% to 15% year-over-year on an organic basis.

January 8, 2018
·
15 min read
Deals

Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio

The close of the acquisition solidifies Melinta’s position as the world’s largest pure-play antibiotics company.

January 8, 2018
·
8 min read
BioForest

Alder Announces $250M Committed Equity Financing

Alder intends to use the cash to fund payments under Alder’s European patent settlement and global license agreement with Teva announced today.

January 8, 2018
·
5 min read
Genetown

TraceLink Industry Lead Widens as Pharmaceutical and Contract Manufacturing Customer Count Nears 400

The Company added 75 new pharmaceutical and CMO customers in Q4 of 2017, with 50 new manufacturing customers added in the month of December alone.

January 8, 2018
·
3 min read
Business

Veritas Genetics Launches Collaboration With Mayo Clinic to Integrate Whole Genome Sequencing Into Clinical Care

Veritas Genetics, The Genome Company, and Mayo Clinic are entering into an agreement to make whole genome sequencing broadly available to healthy individuals.

January 8, 2018
·
2 min read
Pharm Country

Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250M

Royalty Pharma has also purchased $75 million in common stock of Immunomedics.

January 8, 2018
·
6 min read